483 related articles for article (PubMed ID: 11509929)
1. Chronic graft-versus-host disease: clinical manifestation and therapy.
Ratanatharathorn V; Ayash L; Lazarus HM; Fu J; Uberti JP
Bone Marrow Transplant; 2001 Jul; 28(2):121-9. PubMed ID: 11509929
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
5. Life-threatening graft-vs-host disease.
Vargas-Díez E; García-Díez A; Marín A; Fernández-Herrera J
Clin Dermatol; 2005; 23(3):285-300. PubMed ID: 15896544
[TBL] [Abstract][Full Text] [Related]
6. Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model.
Nagler A; Ohana M; Alper R; Doviner V; Sherman Y; Rabbani E; Engelhardt D; Ilan Y
Bone Marrow Transplant; 2003 Aug; 32(4):363-9. PubMed ID: 12900772
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
10. Chronic graft-versus-host disease.
Horwitz ME; Sullivan KM
Blood Rev; 2006 Jan; 20(1):15-27. PubMed ID: 16426941
[TBL] [Abstract][Full Text] [Related]
11. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous graft-versus-host disease: a guide for the dermatologist.
Häusermann P; Walter RB; Halter J; Biedermann BC; Tichelli A; Itin P; Gratwohl A
Dermatology; 2008; 216(4):287-304. PubMed ID: 18230976
[TBL] [Abstract][Full Text] [Related]
13. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA; Bazarbachi A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
[TBL] [Abstract][Full Text] [Related]
15. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
Russell CA
Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
[TBL] [Abstract][Full Text] [Related]
17. Graft-versus-host disease: emerging concepts in prevention and therapy.
Dean RM; Bishop MR
Curr Hematol Rep; 2003 Jul; 2(4):287-94. PubMed ID: 12901325
[TBL] [Abstract][Full Text] [Related]
18. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
19. Extracorporeal photopheresis in chronic graft-versus-host disease.
Foss FM; Gorgun G; Miller KB
Bone Marrow Transplant; 2002 May; 29(9):719-25. PubMed ID: 12040467
[TBL] [Abstract][Full Text] [Related]
20. Response to thalidomide therapy in refractory chronic graft-versus-host disease.
Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H
Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]